Show simple item record

dc.contributor.authorWang, M
dc.contributor.authorBlum, K
dc.contributor.authorMartin, P
dc.contributor.authorGoy, A
dc.contributor.authorAuer, R
dc.contributor.authorKahl, B
dc.contributor.authorJurczak, W
dc.contributor.authorAdvani, R
dc.contributor.authorRomaguera, J
dc.contributor.authorWilliams, M
dc.contributor.authorBarrientos, J
dc.contributor.authorChmielowska, E
dc.contributor.authorRadford, John A
dc.contributor.authorStilgenbauer, S
dc.contributor.authorDreyling, M
dc.contributor.authorJedrzejczak, W
dc.contributor.authorJohnson, P
dc.contributor.authorSpurgeon, S
dc.contributor.authorZhang, L
dc.contributor.authorBaher, L
dc.contributor.authorCheng, M
dc.contributor.authorLee, D
dc.contributor.authorBeaupre, D
dc.contributor.authorRule, S
dc.date.accessioned2015-07-22T14:08:35Zen
dc.date.available2015-07-22T14:08:35Zen
dc.date.issued2015-06-09en
dc.identifier.citationLong-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. 2015: Blooden
dc.identifier.issn1528-0020en
dc.identifier.pmid26059948en
dc.identifier.doi10.1182/blood-2015-03-635326en
dc.identifier.urihttp://hdl.handle.net/10541/560878en
dc.description.abstractIbrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. Herein, we report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-month follow-up). Patients (N=111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study. The primary end point was overall response rate (ORR). The median patient age was 68 years (range, 40-84) with a median of 3 prior therapies (range, 1-5). The median treatment duration was 8.3 months; 46% of patients were treated for >12 months, and 22% were treated for ≥2 years. The ORR was 67% (23% complete response) with a median duration of response of 17.5 months. The 24-month PFS and OS rates were 31% (95% CI: 22.3-40.4) and 47% (95% CI: 37.1-56.9), respectively. The most common adverse events (AEs) in >30% of patients included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%). The most frequent grade ≥3 infections included pneumonia (8%), urinary tract infection (4%), and cellulitis (3%). Grade ≥3 bleeding events in ≥2% of patients were hematuria (2%) and subdural hematoma (2%). Common all-grade hematologic AEs were thrombocytopenia (22%), neutropenia (19%), and anemia (18%). The prevalence of infection, diarrhea, and bleeding was highest for the first 6 months of therapy and less thereafter. With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL. The trial is registered to www.ClinicalTrials.gov as NCT01236391.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Blooden
dc.titleLong-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.en
dc.typeArticleen
dc.contributor.departmentThe University of Texas MD Anderson Cancer Center, Houston, TX, United States;en
dc.identifier.journalBlooden
dc.description.collectionLymphoma Research Teamen
html.description.abstractIbrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. Herein, we report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-month follow-up). Patients (N=111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study. The primary end point was overall response rate (ORR). The median patient age was 68 years (range, 40-84) with a median of 3 prior therapies (range, 1-5). The median treatment duration was 8.3 months; 46% of patients were treated for >12 months, and 22% were treated for ≥2 years. The ORR was 67% (23% complete response) with a median duration of response of 17.5 months. The 24-month PFS and OS rates were 31% (95% CI: 22.3-40.4) and 47% (95% CI: 37.1-56.9), respectively. The most common adverse events (AEs) in >30% of patients included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%). The most frequent grade ≥3 infections included pneumonia (8%), urinary tract infection (4%), and cellulitis (3%). Grade ≥3 bleeding events in ≥2% of patients were hematuria (2%) and subdural hematoma (2%). Common all-grade hematologic AEs were thrombocytopenia (22%), neutropenia (19%), and anemia (18%). The prevalence of infection, diarrhea, and bleeding was highest for the first 6 months of therapy and less thereafter. With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL. The trial is registered to www.ClinicalTrials.gov as NCT01236391.


This item appears in the following Collection(s)

Show simple item record